While a failed ebola drug helped treat hospitalized Covid-19 patients, the common cold virus could become key in treating advanced unresectable cancers.
AstraZeneca and Merck announced positive five-year follow-up data from the Phase III SOLO-1 trial which demonstrated a long-term progression-free survival benefit of Lynparza as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who were in complete or partial response to platinum-based chemotherapy.
A late-stage clinical trial showed therapy combining Roche’s immunotherapy Tecentriq with two of the Swiss drugmaker’s other medicines helped people with a form of advanced melanoma.
A late-stage trial testing a combination of Bristol-Myers Squibb Co.’s cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients.
Shares of Exelixis fell after the company disclosed in a U.S. SEC filing that a Phase III melanoma trial failed to hit endpoints.
Bristol-Myers Squibb Company announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), alone or in combination, in patients with advanced or metastatic melanoma.
A combination of experimental drugs from Array BioPharma Inc. kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late-stage study.
The U.S. FDA granted priority review for Novartis’ Tafinlar in combination with Mekinist for treating some patients with advanced melanoma.
Incyte Corporation will have an abstract published at the European Society for Medical Oncology (ESMO) meeting in early September with new and updated data from its ongoing Phase I/II trial of epacadostat in combination with Merck & Co.’s Keytruda in advanced melanoma.
Bristol-Myers Squibb Co. and Daiichi Sankyo said they were evaluating a combination of Bristol-Myers’ immuno-oncology drug, Opdivo with the Japanese company’s experimental drug in patients with breast and bladder cancers.